Impact of Methylphenidate Formulation on ADHD Treatment
Author Information
Author(s): Kemner Jason E, Lage Maureen J
Primary Institution: McNeil Consumer and Specialty Pharmaceuticals
Hypothesis
The easier treatment regimen associated with once-daily OROS MPH would be associated with improved patient adherence and improved patient outcomes compared to TID dosing of immediate-release MPH.
Conclusion
The use of OROS MPH is associated with fewer gaps in medication, less switches in medication, and more days on therapy, as well as fewer hospitalizations and shorter hospital stays compared to TID MPH.
Supporting Evidence
- Individuals on OROS MPH had significantly fewer gaps in therapy compared to those on TID MPH.
- Patients on OROS MPH were less likely to switch medications than those on TID MPH.
- The average length of therapy was longer for those on OROS MPH.
- Patients on OROS MPH had significantly fewer hospitalizations.
Takeaway
Kids with ADHD who take a once-a-day medicine called OROS MPH do better and stay healthier than those who take it three times a day.
Methodology
The study used a retrospective analysis of a large claims database to compare treatment patterns and hospitalizations between individuals receiving OROS MPH and TID MPH.
Potential Biases
The use of medical claims data may not capture all relevant patient characteristics, such as ethnicity or quality of life.
Limitations
The study's findings may not be generalizable to populations outside of those continuously insured and employed, and it relied on diagnostic codes rather than formal assessments of ADHD severity.
Participant Demographics
The average age was approximately 15, with 23% females and the majority residing in the East.
Statistical Information
P-Value
p < 0.0001
Confidence Interval
0.0945 – 0.1366
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website